Investment, Funding & Disinvestments

The new 250,000-square-foot (23,226-square-metre) Bellwether Laboratory will significantly expand global production capacity for actinium-225 (Ac-225).

Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.

The expansion will also include upgrades to clinical infrastructure and medical equipment, enabling the hospital to deliver more integrated and specialised healthcare services while responding to rising patient demand.

The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.

The new facility is designed to address the growing prevalence of sleep disorders, which remain among the most underdiagnosed health conditions despite their serious impact on long-term wellbeing.

The acquisition builds on an established collaboration between Roche and PathAI that began in 2021 and expanded in 2024 to include the development of AI-enabled companion diagnostic algorithms.

The Sokoto deployment builds on findings from an extensive randomized controlled implementation study conducted in Nigeria in collaboration with PATH, Jhpiego, the National Primary Health Care Development Agency, and Sydani Group.

The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.

Catalyst Pharmaceuticals, listed on Nasdaq in 2006, has evolved into a focused rare disease company with strong commercial momentum.

The initiative will leverage the UAE–India healthcare corridor to expand access to gene therapies for high-need populations and strengthen cross-border biomedical collaboration.